Skip to main content
CMPS
NASDAQ Life Sciences

Compass Completes FDA NDA Submission for Psilocybin Depression Therapy

Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.9
Mkt Cap
$1.218B
52W Low
$4.88
52W High
$15.87
52W Position info
82% above low
Off High info
44% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CMPS sits 82% above its 52-week low of $4.88.

Summary

Compass finished submitting its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression, moving the program from clinical data into the regulatory review phase. This is the key gating step before any U.S. approval, and it follows the positive Phase 3 readouts reported in September. The company says it has a fully scaled commercial organization ready to support launch if approved. The NDA covers a market of roughly 4 million U.S. TRD patients, fewer than 5% of whom are currently on a TRD-indicated treatment. Approval is not assured, and the drug still needs DEA and state rescheduling before it can be commercialized. The FDA review timeline is the next milestone to track.

At the time of this announcement, CMPS was trading at $8.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.88 to $15.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

CMPS - Latest Insights

CMPS
Nov 03, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.21
Real-time Price: $9.21 info
Change: $0 (0%) info
Market Cap: $1.22B info
CMPS
Nov 03, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $9.21 info
Change: -$0.290 (-3%) info
Market Cap: $1.22B info
CMPS
Sep 23, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $9.21 info
Change: -$5.54 (-38%) info
Market Cap: $1.22B info
CMPS
Sep 09, 2026, 1:18 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $15.30
Real-time Price: $9.21 info
Change: -$6.08 (-40%) info
Market Cap: $1.22B info
CMPS
Aug 05, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.84
Real-time Price: $9.21 info
Change: -$2.63 (-22%) info
Market Cap: $1.22B info